The study was done to analyse widefield imaging features, analyse risk factors for progression and compare treatment modalities of peripheral exudative hemorrhagic chorioretinopathy (PEHCR).
Clinical and imaging data from each visit were collected, including near-infrared reflectance, fluorescein angiography, indocyanine green angiography, optical coherence tomography using the Spectralis platform. Clinical features and treatment performed were recorded. 50 eyes of 35 patients were retrospectively enrolled. Peripheral subretinal fluid (SRF) was detected in 62% eyes and peripheral neovascular networks were detected in 84% eyes and
graded as focal, diffuse and subtotal in 44%, 34% and 22% eyes, respectively. MI secondary to PEHCR during the follow-up was documented in 34% eyes, while IVB occurred in 14% eyes. Both MI and IVB correlated with peripheral SRF and lesion grade. Active treatment included anti-vascular endothelial growth factor (anti-VEGF) injections, photodynamic therapy (PDT) and combined anti-VEGF and PDT for 13 (26%), 1 (2%) and 18 (36%) eyes, respectively. In eyes with risk factors, anti-VEGF and combined treatment inversely correlated with MI incidence.
The study concluded that the peripheral subretinal exudation and the extension of peripheral involvement represented risk factors for MI in eyes with PEHCR. In those high-risk eyes, active treatment is warranted.
Reference: https://bjo.bmj.com/content/early/2020/09/03/bjophthalmol-2020-317083
